ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 889

Modeling Environmental and Genetic Determinants to Identify the Association of Risk Genes in Anti-Ro60-Mediated Injury: Relaxin Receptor I and Tumor Necrosis Factor

Joanne H. Reed1, Paula S. Ramos2, Jiri Zavadil3, Jill P. Buyon4 and Robert M. Clancy1, 1Medicine, New York University School of Medicine, New York, NY, 2Department of Medicine, Medical University of South Carolina, Charleston, SC, 3Pathology and Center for Health Informatics and Bioinformtics, New York University School of Medicine, New York, NY, 4Department of Medicine, New York University School of Medicine, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, autoantigens, cytokines and neonatal disorders, RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fetuses exposed to maternal anti-Ro60 antibodies can develop cardiac conduction abnormalities and life threatening cardiomyopathy; manifestations of neonatal lupus (NL). Recent data support an injury model in which immune complexes (IC) comprised of Ro60, ssRNA, and anti-Ro60 engage Toll-like receptors (TLR) and promote secretion of proinflammatory and profibrotic factors.  To identify risk genes related to TLR-dependent fibrosis, a novel strategy was designed based on: 1) gene expression of macrophages stimulated by Ro60-related hY3 ssRNA as a proxy of the in utero environmental contribution and 2) the association of genetic variation with cardiac NL. This is the first approach to employ environmental and genetic determinants to identify the association of risk genes in anti-Ro60-mediated injury.

Methods:  Human macrophages obtained from PBMCs were transfected with hY3 or cultured with IC containing Ro60, anti-Ro60,and hY3 to ligate TLR7 with or without IRS661, a specific TLR7 inhibitor. Affymetrix HG-U133A 2.0 microarray analysis using RNA isolated from the test conditions (n=6) was employed.  Selection was prioritized to expression of genes common to both hY3 and IC stimulation in which the copy number increased by 50%. Ingenuity Pathway Analysis was used to generate a list of genes with fibrotic functions.  Variants from our previously published genome-wide association study (GWAS) were used to test for an enrichment of association in these genes. This list was then compared to the overexpressed transcripts, and shared genes were ranked using a weighted composite score with a focus on the TLR7 pathway (ratio of transcript copy number for IC/IC+IRS661, high to low, and by the P-value of the variant, most significant to least).

Results:   In hY3 and IC stimulated conditions 1184 shared genes were upregulated of which 1110 and 891 were reduced by 50% with IRS661 co-treatment, respectively. Among these, there was an enrichment of genes known to be related to inflammation and fibrosis.  Based on our previously published GWAS, 327 fibrotic genes showed a significant enrichment of associations with cardiac NL (P=2.27×10-9).  Of these genes, 20 were overexpressed in the macrophage array in a TLR7-dependent manner.  To select candidates with a potential functional role in mediating cardiac injury, the candidate list was narrowed to three genes based on a ranking of a composite score. The risk gene with the highest score was the relaxin receptor 1 (RXFP1) (transcript copy number (IC/(IC+IRS661)) ratio=21.2 and rs10517692 P=0.035), a G-protein coupled receptor that binds relaxin and plays a role in collagen and connective tissue remodeling. Key inflammatory mediators included C5 (ratio=6.4, rs2269066 P=0.008) and TNF (ratio=4.1, rs2844482 P=0.004). The latter was previously reported to have both genetic variation and biologic relevance associated with cardiac NL.

Conclusion:  These data support the applicability of a novel model in which causal alleles can be identified by combining expression and association datasets to delineate the molecular mechanisms by which anti-Ro60 antibody mediates cardiac injury. The identification of RXFP1 and the further confirmation of TNF provide important targets for consideration.


Disclosure:

J. H. Reed,
None;

P. S. Ramos,
None;

J. Zavadil,
None;

J. P. Buyon,

NIH 5R37AR042455,

2,

NIH AR42220,

2;

R. M. Clancy,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modeling-environmental-and-genetic-determinants-to-identify-the-association-of-risk-genes-in-anti-ro60-mediated-injury-relaxin-receptor-i-and-tumor-necrosis-factor/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology